Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Medtronic (MDT)
NYSE:MDT
Holding MDT?
Track your performance easily
MDT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$75.96 - $92.68
Previous Close$84.74
Volume6.53M
Average Volume (3M)6.16M
Market Cap
$108.68B
Enterprise Value$128.91B
Total Cash (Recent Filing)$7.84B
Total Debt (Recent Filing)$27.86B
Price to Earnings (P/E)25.8
Beta0.63
Next Earnings
Feb 18, 2025EPS Estimate
$1.36Last Dividend Ex-Date
Sep 27, 2024Dividend Yield3.31%
Share Statistics
EPS (TTM)3.28
Shares Outstanding1,282,490,493
10 Day Avg. Volume8,083,141
30 Day Avg. Volume6,158,343
Standard Deviation0.07
R-Squared0.45
Alpha-0.00892
Financial Highlights & Ratios
Price to Book (P/B)2.25
Price to Sales (P/S)3.35
Price to Cash Flow (P/CF)27.60
P/FCF Ratio45.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.96
Enterprise Value/Gross Profit6.10
Enterprise Value/Ebitda15.57
Forecast
1Y Price Target
$96.21Price Target Upside11.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
Medtronic News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceMedtronic delivered its eighth consecutive quarter of mid-single-digit revenue growth and another EPS beat.
Product Approvals And LaunchesMedtronic has received FDA approval for the Affera PFA platform and CMS TPT payment approval for the Symplicity renal denervation system, with further FDA submission for Hugo planned.
Revenue Growth And GuidanceMedtronic raised its fiscal year 2025 organic revenue guidance to a range of 4.75-5.0%, indicating confidence in future performance.
Bears Say
Financial PerformanceAdjusted operating margin was slightly below expectations, reflecting ongoing supply chain pressures and cost-saving program delays.
Investment And Market PerceptionDespite the solid performance, Medtronic remains comparatively under-owned by larger long-only funds, which could affect market perception.
Market Position And CompetitionThe growing popularity of GLP-1 drugs could significantly impact Medtronic's insulin pump sales, with a risk of losing 50% of its market share.
---
Ownership Overview
0.07% Insiders
24.94% Mutual Funds
18.64% Other Institutional Investors
36.20% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MDT FAQ
What was Medtronic’s price range in the past 12 months?
Medtronic lowest stock price was $75.96 and its highest was $92.68 in the past 12 months.
What is Medtronic’s market cap?
Currently, no data Available
When is Medtronic’s upcoming earnings report date?
Medtronic’s upcoming earnings report date is Feb 18, 2025 which is in 87 days.
How were Medtronic’s earnings last quarter?
Medtronic released its earnings results on Nov 19, 2024. The company reported $1.26 earnings per share for the quarter, beating the consensus estimate of $1.25 by $0.01.
Is Medtronic overvalued?
According to Wall Street analysts Medtronic’s price is currently Undervalued.
Does Medtronic pay dividends?
Medtronic pays a Quarterly dividend of $0.7 which represents an annual dividend yield of 3.31%. See more information on Medtronic dividends here
What is Medtronic’s EPS estimate?
Medtronic’s EPS estimate is $1.36.
How many shares outstanding does Medtronic have?
Medtronic has 1,282,490,500 shares outstanding.
What happened to Medtronic’s price movement after its last earnings report?
Medtronic reported an EPS of $1.26 in its last earnings report, beating expectations of $1.25. Following the earnings report the stock price went down -2.957%.
Which hedge fund is a major shareholder of Medtronic?
Among the largest hedge funds holding Medtronic’s share is First Eagle Investment Management LLC. It holds Medtronic’s shares valued at 879M.
---
Medtronic Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$96.21 (11.60% Upside)
$96.21 (11.60% Upside)
Blogger Sentiment
Bullish
MDT Sentiment 95%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 889.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.43%
12-Months-Change
Fundamentals
Return on Equity
8.58%
Trailing 12-Months
Asset Growth
-0.05%
Trailing 12-Months
Company Description
Medtronic
Founded in 1949, Medtronic Plc, a medical technology company, develops, manufactures, distributes, and sells device-based medical therapies and services worldwide. It operates through four segments, including Cardiac and Vascular Group; Minimally Invasive Technologies Group; Restorative Therapies Group; and Diabetes Group. The company is headquartered in Dublin, Ireland.
---
MDT Company Deck
---
MDT Earnings Call
Q2 2024
0:00 / 0:00
---
MDT Net sales Breakdown
36.56% Cardiovascular
29.06% Neuroscience
26.01% Medical Surgical
7.69% Diabetes
0.68% Other operating segment
---
MDT Stock 12 Month Forecast
Average Price Target
$96.21
▲(11.60% Upside)
Technical Analysis
Best Analysts Covering MDT
1 Year
1 Year Success Rate
19/22 ratings generated profit
1 Year Average Return
+15.04%
reiterated a buy rating 12 months ago
Copying Kristen Stewart's trades and holding each position for 1 Year would result in 86.36% of your transactions generating a profit, with an average return of +15.04% per trade.
---